Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study.

Young AM, DiClemente RJ, Halgin DS, Sterk CE, Havens JR.

BMC Public Health. 2014 May 30;14:537. doi: 10.1186/1471-2458-14-537.

2.

Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination.

Young AM, Halgin DS, Havens JR.

AIDS Care. 2015;27(8):1000-4. doi: 10.1080/09540121.2015.1017443. Epub 2015 Mar 2.

3.

Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Young AM, DiClemente RJ, Halgin DS, Sterk CE, Havens JR.

AIDS Behav. 2014 Sep;18(9):1753-63. doi: 10.1007/s10461-014-0797-9.

4.

Willingness of Chinese injection drug users to participate in HIV vaccine trials.

Yin L, Zhang Y, Qian HZ, Rui B, Zhang L, Zhu J, Guan Y, Wang Y, Li Q, Ruan Y, Shao Y.

Vaccine. 2008 Feb 6;26(6):762-8. doi: 10.1016/j.vaccine.2007.11.091. Epub 2007 Dec 26.

5.

Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.

Celentano DD, Beyrer C, Natpratan C, Eiumtrakul S, Sussman L, Renzullo PO, Khamboonruang C, Nelson KE.

AIDS. 1995 Sep;9(9):1079-83.

PMID:
8527082
6.

Differences in HIV vaccine acceptability between genders.

Kakinami L, Newman PA, Lee SJ, Duan N.

AIDS Care. 2008 May;20(5):542-6. doi: 10.1080/09540120701867180.

7.

Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.

Newman PA, Roungprakhon S, Tepjan S, Yim S.

Vaccine. 2010 Jan 22;28(4):958-64. doi: 10.1016/j.vaccine.2009.10.142. Epub 2009 Nov 17.

PMID:
19925897
8.

Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.

Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P, Guadamuz T, Suwanvanichkij V, Beyrer C, Chariyalertsak S.

PLoS One. 2013 Oct 8;8(10):e76650. doi: 10.1371/journal.pone.0076650. eCollection 2013.

9.

HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics.

Newman PA, Duan N, Lee SJ, Rudy ET, Seiden DS, Kakinami L, Cunningham WE.

Vaccine. 2006 Mar 15;24(12):2094-101. Epub 2005 Nov 21.

10.

HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.

Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, Krishna N, Teshale EH, Paz-Bailey G; National HIV Behavioral Surveillance System Study Group..

MMWR Surveill Summ. 2014 Jul 4;63(6):1-51.

11.

Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns.

Weiser SD, Heisler M, Leiter K, Percy-de Korte F, Tlou S, DeMonner S, Phaladze N, Bangsberg DR, Iacopino V.

PLoS Med. 2006 Jul;3(7):e261. Erratum in: PLoS Med. 2006 Oct;3(10):e395.

12.

Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.

Jackson DJ, Martin HL Jr, Bwayo JJ, Nyange PM, Rakwar JP, Kashonga F, Mandaliya K, Ndinya-Achola JO, Kreiss JK.

AIDS. 1995 Nov;9(11):1279-83.

PMID:
8561982
13.

Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES.

Lee SJ, Newman PA, Duan N, Cunningham WE.

Vaccine. 2014 Sep 3;32(39):5013-8. doi: 10.1016/j.vaccine.2014.07.018. Epub 2014 Jul 18.

14.

Risk factors for HIV seropositivity in a sample of drug users in drug treatment in Ho Chi Minh City, Vietnam.

Tran SD, Williams AB, Truong HT, Do NH.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):283-7.

PMID:
9495230
15.

Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.

Young AM, Halgin DS, DiClemente RJ, Sterk CE, Havens JR.

PLoS One. 2014 Jul 3;9(7):e101047. doi: 10.1371/journal.pone.0101047. eCollection 2014.

16.

Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users.

Dhalla S, Poole G, Singer J, Patrick DM, Wood E, Kerr T.

Vaccine. 2010 Feb 17;28(7):1663-7. doi: 10.1016/j.vaccine.2009.12.023. Epub 2009 Dec 29.

17.

Prevalence and correlates of willingness to participate in a rectal microbicide trial among men who have sex with men in Bangkok.

Thienkrua W, Todd CS, Chaikummao S, Sukwicha W, Yafant S, Tippanont N, Varangrat A, Khlaimanee P, Holtz TH.

AIDS Care. 2014;26(11):1359-69. doi: 10.1080/09540121.2014.913763. Epub 2014 May 6.

PMID:
24797186
18.

Endorsement of compulsory HIV vaccination policy among populations at high risk of HIV exposure (LA VOICES).

Newman PA, Lee SJ, Rudy ET, Diamant A, Duan N, Nakazono T, Cunningham WE.

Prev Sci. 2014 Jun;15(3):428-35. doi: 10.1007/s11121-014-0463-5. Erratum in: Prev Sci. 2014 Jun;15(3):436. Nakazano, Terry [corrected to Nakazono, Terry].

19.

Oral cancer screening and dental care use among women from Ohio Appalachia.

Reiter PL, Wee AG, Lehman A, Paskett ED.

Rural Remote Health. 2012;12:2184. Epub 2012 Dec 17.

20.

Pediatric HIV type 1 vaccine trial acceptability among mothers in Kenya.

Farquhar C, John-Stewart GC, John FN, Kabura MN, Kiarie JN.

AIDS Res Hum Retroviruses. 2006 Jun;22(6):491-5.

Supplemental Content

Support Center